caffeine and Diabetes Mellitus, Gestational studies

Research Excerpts

Excerpt	Relevance	Reference
"Compounds other than macronutrients have been shown to influence blood glucose concentrations and insulin sensitivity in people with diabetes, with caffeine being one such substance."	8.89	Systematic review of randomised controlled trials of the effects of caffeine or caffeinated drinks on blood glucose concentrations and insulin sensitivity in people with diabetes mellitus. ( White, H; Whitehead, N, 2013)
"To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH])."	8.02	Assessment of Caffeine Consumption and Maternal Cardiometabolic Pregnancy Complications. ( Gleason, JL; Grantz, KL; Grewal, J; Hinkle, SN; Mumford, SL; Sundaram, R; Yisahak, SF; Zhang, C; Zhao, SK, 2021)
"Recent work showing that caffeine impairs glucose tolerance may be of particular concern in pregnancy because of a possible negative effect on fetal outcome."	5.14	Acute caffeine ingestion and glucose tolerance in women with or without gestational diabetes mellitus. ( Graham, TE; Robinson, LE; Smith, GN; Spafford, C, 2009)
"Compounds other than macronutrients have been shown to influence blood glucose concentrations and insulin sensitivity in people with diabetes, with caffeine being one such substance."	4.89	Systematic review of randomised controlled trials of the effects of caffeine or caffeinated drinks on blood glucose concentrations and insulin sensitivity in people with diabetes mellitus. ( White, H; Whitehead, N, 2013)
"To determine whether caffeinated-beverage intake and plasma caffeine and paraxanthine are associated with cardiometabolic complications in pregnancy (ie, gestational diabetes [GDM], preeclampsia, and gestational hypertension [GH])."	4.02	Assessment of Caffeine Consumption and Maternal Cardiometabolic Pregnancy Complications. ( Gleason, JL; Grantz, KL; Grewal, J; Hinkle, SN; Mumford, SL; Sundaram, R; Yisahak, SF; Zhang, C; Zhao, SK, 2021)
"The pregnancy was complicated by maternal gestational diabetes mellitus and pre-eclampsia."	1.46	A Newborn Infant With Oxygen Desaturation During Sleep. ( Daftary, A; Deschamp, A, 2017)

Research

Studies (10)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

2 Hours Plasma Glucose (2-h PG)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (40.00)	29.6817
2010's	4 (40.00)	24.3611
2020's	2 (20.00)	2.80

Authors	Studies
Hinkle, SN	2
Gleason, JL	1
Yisahak, SF	1
Zhao, SK	1
Mumford, SL	1
Sundaram, R	1
Grewal, J	1
Grantz, KL	1
Zhang, C	1
Chen, LW	1
Laughon, SK	1
Catov, JM	1
Olsen, J	1
Bech, BH	1
Simhan, HN	1
Deschamp, A	1
Daftary, A	1
Robinson, LE	1
Spafford, C	1
Graham, TE	1
Smith, GN	1
Whitehead, N	1
White, H	1
Reece, EA	1
Wisborg, K	1
Adeney, KL	1
Williams, MA	1
Schiff, MA	1
Qiu, C	1
Sorensen, TK	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of the Administration of Chlorogenic Acid on Glucemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance[NCT02621060]	Phase 2	30 participants (Actual)	Interventional	2015-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Subjects underwent a 2-h oral glucose tolerance test (2-h OGTT) by consuming 75-g of a dextrose load, and one sample was obtained 120 min after glucose administration. (NCT02621060)
Timeframe: Week 12.

Area Under the Curve of Glucose

Intervention	mmol/L (Mean)
Placebo	9.0
Chlorogenic Acid	8.5

Area under the curve of glucose was obtained using the trapezoidal integration. (NCT02621060)
Timeframe: Week 12.

Area Under the Curve of Insulin

Intervention	mmol/l/min (Mean)
Placebo	1187
Chlorogenic Acid	1145

Before and after intervention area under the curve of insulin (NCT02621060)
Timeframe: Week 12.

Body Mass Index

Intervention	pmol/L/min (Mean)
Placebo	67,322
Chlorogenic Acid	72,857

The Body Mass index was calculated at baseline and at week 12 with the Quetelet index and the entered values reflect the body mass index at week 12 (NCT02621060)
Timeframe: Week 12.

Body Weight

Intervention	kg/m^2 (Mean)
Placebo	32.0
Chlorogenic Acid	31.4

The weight was measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the weight at week 12 (NCT02621060)
Timeframe: Week 12.

Creatinine

Intervention	kg (Mean)
Placebo	81.3
Chlorogenic Acid	80.8

The creatinine levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the uric acid levels at week 12 (NCT02621060)
Timeframe: Week 12.

Diastolic Blood Plessure (DBP)

Intervention	mmol/L (Mean)
Placebo	0.06
Chlorogenic Acid	0.06

The Diastolic blood plessure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12 (NCT02621060)
Timeframe: Week 12.

Fasting Plasma Glucose (FPG)

Intervention	mmHg (Mean)
Placebo	78
Chlorogenic Acid	74

Reflect the fasting glucose level after a 10- to 12-h overnight fast. (NCT02621060)
Timeframe: Week 12.

First Phase of Insulin Secretion

Glutamic Oxaloacetic Transaminase (GOT)

Intervention	mmol/L (Median)
Placebo	5.8
Chlorogenic Acid	5.5

Intervention	Unitless (Mean)
Placebo	1281
Chlorogenic Acid	1133

Before and after intervention by spectrophotometry (NCT02621060)
Timeframe: Week 12.

Glutamic Pyruvic Transaminase (GPT)

Intervention	IU/L (Mean)
Placebo	22.03
Chlorogenic Acid	17.79

Before and after intervention by spectrophotometry (NCT02621060)
Timeframe: Week 12.

Glycated Hemoglobin A1c (A1C)

Intervention	IU/L (Mean)
Placebo	25.25
Chlorogenic Acid	22.64

Shows what a person's average blood glucose level was for the 2 to 3 months before the test high-performance. (NCT02621060)
Timeframe: Week 12.

High-density Lipoprotein Cholesterol (HDL-C)

Intervention	Percentage of A1C (Mean)
Placebo	5.8
Chlorogenic Acid	5.5

The HDL-C levels were evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the HDL-C level at week 12 (NCT02621060)
Timeframe: Week 12.

Insulin Sensitivity

Low-density Lipoprotein Cholesterol (LDL-C)

Intervention	mmol/L (Mean)
Placebo	1.5
Chlorogenic Acid	1.8

Intervention	Unitless (Mean)
Placebo	2.43
Chlorogenic Acid	2.30

The LDL-C levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the LDL-C levels at week 12 (NCT02621060)
Timeframe: Week 12.

Systolic Blood Pressure (SBP)

Intervention	mmol/L (Mean)
Placebo	2.7
Chlorogenic Acid	1.9

The Systolic Blood Pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12 (NCT02621060)
Timeframe: Week 12.

Total Cholesterol (TC)

Intervention	mmHg (Mean)
Placebo	118
Chlorogenic Acid	113

The total cholesterol was estimated by standardized techniques at baseline and week 12 and the entered values reflect the total cholesterol level at week 12 (NCT02621060)
Timeframe: Week 12.

Total Insulin Secretion

Intervention	mmol/L (Mean)
Placebo	5.3
Chlorogenic Acid	4.3

After intervention. Total insulin secretion was calculated with the Insulinogenic index (Δ ABC insulin / Δ ABC glucose). (NCT02621060)
Timeframe: Week 12.

Triglycerides (TG)

Intervention	Unitless (Mean)
Placebo	0.55
Chlorogenic Acid	0.63

The triglycerides were evaluated at baseline and week 12 with enzymatic-colorimetric techniques and the entered values reflect the triglycerides level at week 12 (NCT02621060)
Timeframe: Week 12.

Uric Acid

Intervention	mmol/L (Mean)
Placebo	1.7
Chlorogenic Acid	1.3

The uric acid levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the creatinina levels at week 12. (NCT02621060)
Timeframe: Week 12.

Very-low Density Lipoprotein (VLDL)

Intervention	mmol/l (Mean)
Placebo	0.34
Chlorogenic Acid	0.30

The VLDL levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the c-LDL levels at week 12 (NCT02621060)
Timeframe: Week 12.

Waist Circumference (WC)

Intervention	mmol/L (Mean)
Placebo	0.77
Chlorogenic Acid	0.61

Waist circumference was evaluated at baseline and at week 12 with a flexible tape and the entered values reflects the waist circumference measure at week 12 (NCT02621060)
Timeframe: Week 12.

Article	Year
Assessment of Caffeine Consumption and Maternal Cardiometabolic Pregnancy Complications. JAMA network open, 2021, 11-01, Volume: 4, Issue:11 Topics: Adult; Beverages; Caffeine; Cardiometabolic Risk Factors; Cohort Studies; Diabetes, Gestational; Fem	2021
Is it caffeine? Coffee consumption and future risk of type 2 diabetes among women with a history of gestational diabetes. The American journal of clinical nutrition, 2022, 12-19, Volume: 116, Issue:6 Topics: Caffeine; Coffee; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Pregnancy; Prosp	2022
First trimester coffee and tea intake and risk of gestational diabetes mellitus: a study within a national birth cohort. BJOG : an international journal of obstetrics and gynaecology, 2015, Volume: 122, Issue:3 Topics: Adult; Caffeine; Coffee; Cohort Studies; Denmark; Diabetes, Gestational; Female; Humans; Infant, New	2015
Coffee and tea consumption in pregnancy not associated with gestational diabetes mellitus. BJOG : an international journal of obstetrics and gynaecology, 2015, Volume: 122, Issue:3 Topics: Caffeine; Coffee; Diabetes, Gestational; Female; Humans; Male; Pregnancy; Pregnancy Trimester, First	2015
A Newborn Infant With Oxygen Desaturation During Sleep. Chest, 2017, Volume: 151, Issue:1 Topics: Apgar Score; Caffeine; Central Nervous System Stimulants; Diabetes, Gestational; Female; Gestational	2017
Synopsis of the North American Diabetes in Pregnancy Study Group Conference in Little Rock, Arkansas, May 2003. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2004, Volume: 15, Issue:1 Topics: Blood Glucose; Caffeine; Cesarean Section; Congenital Abnormalities; Delivery, Obstetric; Diabetes,	2004
Lifestyle during pregnancy and evidence based information. Acta obstetricia et gynecologica Scandinavica, 2007, Volume: 86, Issue:2 Topics: Caffeine; Coffee; Diabetes, Gestational; Female; Humans; Life Style; Pregnancy	2007
Coffee consumption and the risk of gestational diabetes mellitus. Acta obstetricia et gynecologica Scandinavica, 2007, Volume: 86, Issue:2 Topics: Adult; Caffeine; Central Nervous System Stimulants; Coffee; Diabetes, Gestational; Dose-Response Rel	2007

caffeine and Diabetes Mellitus, Gestational